Fig. 2.

Kaplan-Meier analysis for disease progression according to 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) level doubling time (DT) in the entire cohort (n = 49, A) and only patients with small-intestine neuroendocrine tumors (NETs), or with NET of unknown primary location (n = 19, B), and only patients with pancreatic NETs (n = 23, C).